Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
grade D 13.24 -13.12% -2.00
OMER closed up 6.05 percent on Wednesday, December 4, 2019, on 3.23 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical OMER trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish -13.12%
Crossed Above 50 DMA Bullish -13.12%
Pocket Pivot Bullish Swing Setup -13.12%
Volume Surge Other -13.12%
Doji - Bearish? Reversal -13.12%
Above Upper BB Strength -13.12%
Overbought Stochastic Strength -13.12%
Upper Bollinger Band Touch Strength -13.12%
Weak + Overbought Other -7.86%
Overbought Stochastic Strength -7.86%

Older signals for OMER ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Medicine Biopharmaceutical Health Medical Specialties Surgery Inflammation Clinical Trial Disorders Schizophrenia Ophthalmology Clinical Research Wet Age Related Macular Degeneration Movement Disorders Urology Cataract Paroxysmal Nocturnal Hemoglobinuria Surgical Specialties Cognitive Disorders Arthroscopy Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicators
Indicator Value
52 Week High 20.92
52 Week Low 10.3
Average Volume 408,147
200-Day Moving Average 16.7443
50-Day Moving Average 15.0529
20-Day Moving Average 14.0355
10-Day Moving Average 14.489
Average True Range 0.7483
ADX 14.07
+DI 29.5672
-DI 16.381
Chandelier Exit (Long, 3 ATRs ) 13.6351
Chandelier Exit (Short, 3 ATRs ) 14.8749
Upper Bollinger Band 15.1241
Lower Bollinger Band 12.9469
Percent B (%b) 1.05
BandWidth 15.512094
MACD Line -0.1161
MACD Signal Line -0.3128
MACD Histogram 0.1967
Fundamentals Value
Market Cap 682.79 Million
Num Shares 44.8 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -10.37
Price-to-Sales 11.55
Price-to-Book 0.00
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.30
Resistance 3 (R3) 17.28 16.58 16.95
Resistance 2 (R2) 16.58 16.06 16.59 16.84
Resistance 1 (R1) 15.91 15.73 15.56 15.93 16.72
Pivot Point 15.21 15.21 15.04 15.22 15.21
Support 1 (S1) 14.54 14.69 14.19 14.56 13.76
Support 2 (S2) 13.84 14.36 13.85 13.64
Support 3 (S3) 13.17 13.84 13.53
Support 4 (S4) 13.19